Evaluation of the impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib treatment for the treatment of chemo-resistant metastatic colorectal cancers
Colon-Rectum
Digestif
Phase III